Lab to Startup

Lab to Startup

Hundreds of thousands of researchers around the world are working to improve life and address imminent threats to humanity. Often, the research ends up in the “Scientific valley of death” in the form of publications and patents that never see the light of the day.

Welcome to “Lab to Startup” a podcast aimed at showcasing the effort needed to translate lab research to startups. The show has two main goals: 1. Sharing the stories of those scientists and engineers who have successfully fou…

Recent Episodes

View all
Biotech's New Rules: Tight Capital, Hard Science, AI, and Survival in 2026
62
March 2, 2026

Biotech's New Rules: Tight Capital, Hard Science, AI, and Survival in 2026

Doug Crawford, Ph.D., is the founder of MBC BioLabs and also a Managing General Partner of Mission BioCapital. Doug’s goal is to help entrepreneurial scientists create successful startups. His dream is that every entrepreneurial scientist with a dream be given a chance. Since its founding, this program has helped launch 500 companies and helped raise over $20 billion in capital. Robert Blazej, Ph.D., is a Partner at Mission BioCapital and Director at MBC BioLabs. He is a passionate biotechnolog
Listen to the Episode
Cold Plasma Meets Machine Learning: The SirenOpt Story of Solving Manufacturing's Nanoscale Blind Spot
61
Jan. 19, 2026

Cold Plasma Meets Machine Learning: The SirenOpt Story of Solving Manufacturing's Nanoscale Blind Spot

Jared O'Leary, Ph.D., is the co-founder and CEO of SirenOpt, and Ali Mesbah, Ph.D. is his cofounder and also his former PhD advisor. Ali is a Professor of Chemical Engineering at UC Berkeley. SirenOpt is a Berkeley spin-out that is solving one of manufacturing's biggest blind spots. Their PlasmaSens platform uses cold atmospheric plasma and AI to non-destructively inspect thin films and nanomaterials in real-time—catching defects and inconsistencies that traditional methods miss entirely. They'r
Listen to the Episode
Designing the Future of Drug Delivery: How AI is Solving RNA's Biggest Challenge
60
Dec. 8, 2025

Designing the Future of Drug Delivery: How AI is Solving RNA's Biggest Challenge

Yogev Debbi and Prof Avi Schroeder (Technion Israel Institute of Technology), co-founded Mana bio along with Dr. Kira Radinsky and Roy Nevo . They are leveraging data, machine learning and high throughput screening to design novel Lipid NanoParticles for targeted extrahepatic delivery of nucleic acid therapeutics and vaccines. Lipid nanoparticles are microscopic fatty bubbles that deliver genetic medicines into your cells—think of them as the FedEx trucks of molecular biology. Remember the mRNA
Listen to the Episode
Solving the CRISPR delivery problem using a proprietary peptide-based platform
59
May 19, 2025

Solving the CRISPR delivery problem using a proprietary peptide-based platform

Dana Foss and Ross Wilson are the cofounders of Editpep, a biotech startup focused on developing CRISPR-based therapeutics. They are using a proprietary peptide-based delivery platform that enables targeted delivery to specific cell types, particularly for hard-to-reach areas like the brain. While Dana Foss is the CEO, Ross Wilson is also an Assistant Adjunct Professor of Molecular and Cell Biology and also the Director of Therapeutic Delivery at the Innovative Genomics Institute at the Universi
Listen to the Episode
Altitude Lab Fund- Supporting healthcare founders in challenging times
58
March 11, 2025

Altitude Lab Fund- Supporting healthcare founders in challenging times

Chandana Haque is the Executive Director of Altitude Lab, a healthcare startup accelerator building a community of diverse entrepreneurs in Utah. Altitude Lab was cofounded in 2020 by Chandana and Chris Gibson, the co-founder & CEO of Recursion in...
Listen to the Episode
Partnering to accelerate therapeutics: A primer on forming alliances and their management
57
Dec. 10, 2024

Partnering to accelerate therapeutics: A primer on forming alliances and their management

Monica Rosoff, the founder and CEO of LBBAL™ Alianza. Prior to launching Alianza, Monica was a partnering executive with roles of increasing seniority at Genentech, Gilead, Kite and Exelixis. Over the course of over two decades, she had the...
Listen to the Episode
View all Episodes